接受直接抗病毒治疗的患者中持续病毒血症的发生率及其对持续病毒学应答率的影响
Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy.
作者信息
Carver Alicia B, Zuckerman Autumn D, DeClercq Joshua, Choi Leena, Chastain Cody A
机构信息
Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
出版信息
Open Forum Infect Dis. 2020 Nov 26;7(12):ofaa569. doi: 10.1093/ofid/ofaa569. eCollection 2020 Dec.
Abstract
Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.
摘要
在一个由983名患者组成的真实世界队列中，接受直接抗病毒治疗时的持续病毒血症（PV）发生率较低（5.7%）。PV患者（92.9%）和病毒学快速应答患者（96.5%）均实现了较高的持续病毒学应答率，且无显著差异。
相似文献
1
Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy.接受直接抗病毒治疗的患者中持续病毒血症的发生率及其对持续病毒学应答率的影响
Open Forum Infect Dis. 2020 Nov 26;7(12):ofaa569. doi: 10.1093/ofid/ofaa569. eCollection 2020 Dec.
2
Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.直接作用抗病毒药物的持续病毒学应答可预测丙型肝炎病毒感染患者的更好结局：一项回顾性研究。
World J Gastroenterol. 2019 Oct 28;25(40):6094-6106. doi: 10.3748/wjg.v25.i40.6094.
3
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.直接作用抗病毒药物治疗后成功的丙型肝炎病毒复发，随后发生肝细胞癌肉瘤样改变：一例报告。
J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.
4
Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.丙型肝炎直接抗病毒治疗方案的比较疗效：来自退伍军人管理局的数据。
J Gastroenterol Hepatol. 2017 Jun;32(6):1136-1142. doi: 10.1111/jgh.13652.
5
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.正在接受药物治疗的吸毒者和接受阿片类药物替代治疗者对直接作用抗病毒治疗的反应。
J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8.
6
7
American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.美国胃肠病学会协会临床实践更新-专家评论：慢性丙型肝炎感染抗病毒治疗后获得持续病毒学应答患者的治疗。
Gastroenterology. 2017 May;152(6):1578-1587. doi: 10.1053/j.gastro.2017.03.018. Epub 2017 Mar 23.
8
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.慢性丙型肝炎退伍军人应用直接作用抗病毒药物的早期病毒学应答和血液学安全性。
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7. doi: 10.1016/j.cgh.2013.03.006. Epub 2013 Mar 21.
9
Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease.直接作用抗病毒治疗的持续病毒学应答对晚期肝病患者死亡率的影响。
Hepatology. 2019 Feb;69(2):487-497. doi: 10.1002/hep.29408. Epub 2018 May 15.
10
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.在大型基于人群的队列中，使用直接作用抗病毒治疗成功治疗后丙型肝炎病毒再感染。
J Hepatol. 2018 Nov;69(5):1007-1014. doi: 10.1016/j.jhep.2018.07.025. Epub 2018 Aug 22.
引用本文的文献
1
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.肝脏疾病和低治疗依从性限制丙型肝炎治愈：澳大利亚真实世界治疗队列研究。
Dig Dis Sci. 2023 Jan;68(1):291-303. doi: 10.1007/s10620-022-07483-y. Epub 2022 May 13.
本文引用的文献
1
Evaluating statistical approaches to leverage large clinical datasets for uncovering therapeutic and adverse medication effects.评估利用大型临床数据集发现治疗效果和药物不良反应的统计方法。
Bioinformatics. 2018 Sep 1;34(17):2988-2996. doi: 10.1093/bioinformatics/bty306.
2
Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.丙型肝炎直接抗病毒治疗第4周时HCV RNA水平的意义
J Viral Hepat. 2017 Nov;24(11):966-975. doi: 10.1111/jvh.12731. Epub 2017 Jul 12.
3
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.接受索磷布韦联合疗法治疗的丙型肝炎病毒（HCV）患者治疗结束时RNA阳性/持续病毒学应答的发生率
Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.
4
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.第 4 周的应答可预测丙型肝炎病毒 3 型感染肝硬化患者接受全口服直接抗病毒药物治疗的持续病毒学应答。
Clin Microbiol Infect. 2017 Jun;23(6):409.e5-409.e8. doi: 10.1016/j.cmi.2016.12.034. Epub 2017 Jan 28.
5
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.在 4365 例初治、基因 1 型丙型肝炎感染患者中，使用 ledipasvir/sofosbuvir 的真实世界疗效。
Hepatology. 2016 Aug;64(2):405-14. doi: 10.1002/hep.28625. Epub 2016 Jun 7.
6
Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.应答指导疗法已死？治疗第4周时丙型肝炎病毒仍可检测到的患者治愈率低。
Hepatol Int. 2016 Jul;10(4):624-31. doi: 10.1007/s12072-016-9725-6. Epub 2016 Apr 20.
7
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.不同索磷布韦为基础的抗病毒方案治疗过程中 HCV RNA 水平的临床价值。
J Hepatol. 2016 Sep;65(3):473-82. doi: 10.1016/j.jhep.2016.04.006. Epub 2016 Apr 13.
8
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.注册试验中无干扰素联合直接抗病毒治疗期间的丙型肝炎病毒RNA水平
Clin Infect Dis. 2015 Aug 15;61(4):666-7. doi: 10.1093/cid/civ402. Epub 2015 May 22.
9
Managing Hepatitis C in Users of Illicit Drugs.对非法药物使用者的丙型肝炎管理
Curr Hepat Rep. 2007;6(2):60-67. doi: 10.1007/s11901-007-0005-8.
10
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.研究电子数据采集（REDCap）——一种用于提供转化研究信息学支持的元数据驱动方法和工作流程。
J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
Zotero 插件